261/2
Evaluation of Shoulder Access Safety Using the NewMan Compression Device
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT07714824/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 229 чел. во всех странах исследования.
- Центров в реестре: 1 в одном городе. Список — ниже на странице.
- Плановая дата окончания (06.2026) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 3
Критерии включения
- arterial diameter at the access site of at least 3 mm
- indications for endovascular intervention on the lower extremity arteries
- age of 18 years or more, and patient consent to participate in the study
Критерии невключения
- inability to perform an access due to stenotic lesions of the above-mentioned arteries (axillary, subclavian arteries, and brachiocephalic trunk)
- height exceeding 180 cm; presence of concomitant pathology that limits patient survival; pathology of the blood coagulation system (hemophilia, thrombocytopathies, etc.)
- previous catheterizations performed through the access artery
Источник: ClinicalTrials.gov, NCT07714824 · запись обновлена в реестре 24 июля 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (6), вторичных — 2
- Number of participants with hematoma at the access point with treatment-related adverse events as assessed by CTCAE v4.0 — Within 72 hours after artery catheterization
- Number of participants with Acute artery occlusion with treatment-related adverse events as assessed by CTCAE v4.0 — Within 72 hours after artery catheterization
- Number of participants with Post-catheterization aneurysm that required surgery with treatment-related adverse events as assessed by CTCAE v4.0 — Within 72 hours after artery catheterization
- Number of participants with Technical success of access — Perioperative/Periprocedural
- Number of participants with Technical success of the index procedure — Perioperative/Periprocedural
- Number of participants with Conversion to another access — Perioperative/Periprocedural
Цель исследования
The aim of the study is to evaluate the effectiveness of the NewMan compression device in shoulder access in patients with occlusive lesions of the femoral-popliteal segment of the lower extremity arteries by comparing the frequency of access complications when it is used or when a pressure bandage is used.
The objectives of the study are to answer the following main questions: 1. Does the use of a compression device in shoulder access reduce the overall number of complications compared to an occlusive bandage? 2. Does the use of a compression device during shoulder access reduce the number of complications requiring surgical intervention compared to an occlusive bandage? 3. Does the use of a compression device during shoulder access reduce the number of hematomas in the access area compared to an occlusive bandage? The researchers will compare the number of complications associated with shoulder access when using a compression device and an occlusive bandage for the revascularization of femoral-popliteal segment occlusions of the lower extremity arteries. During the routine revascularization procedure, participants will undergo a catheterization of the brachial artery. Complications related to radiation therapy will be recorded by doctors within 72 hours of the intervention.
Где проходит
1 центр в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT07714824 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.